TRKA (G595R/G667A)
Sign in to save this workspaceNTRK1 · Variant type: compound · HGVS: p.G595R;p.G667A
Components
p.G595Rp.G667A
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Ponatinib | 100.0% | 0.0% | 78.23 |
| 2 | Repotrectinib | 100.0% | 0.0% | 84.21 |
| 3 | Entrectinib | 97.1% | 2.9% | 93.69 |
| 4 | Darovasertib | 92.9% | 7.1% | 96.99 |
| 5 | Cabozantinib | 89.6% | 10.4% | 92.73 |
| 6 | Nintedanib | 63.2% | 36.8% | 90.23 |
| 7 | Pralsetinib | 56.7% | 43.3% | 93.43 |
| 8 | Defactinib | 47.3% | 52.7% | 92.68 |
| 9 | Ripretinib | 40.0% | 60.0% | 92.95 |
| 10 | Crizotinib | 37.0% | 63.0% | 91.39 |
| 11 | Sorafenib | 27.6% | 72.4% | 96.72 |
| 12 | Alpelisib | 26.8% | 73.2% | 97.22 |
| 13 | Tivozanib | 21.7% | 78.3% | 92.42 |
| 14 | Bosutinib | 21.3% | 78.7% | 87.22 |
| 15 | Fedratinib | 19.1% | 80.9% | 96.21 |
| 16 | Tenalisib | 14.1% | 85.9% | 97.98 |
| 17 | Regorafenib | 13.7% | 86.3% | 95.99 |
| 18 | Pacritinib | 13.7% | 86.3% | 88.64 |
| 19 | Ruxolitinib | 13.6% | 86.4% | 98.25 |
| 20 | Sunitinib | 12.9% | 87.1% | 91.73 |
| 21 | Duvelisib | 10.1% | 89.9% | 100.00 |
| 22 | Encorafenib | 9.9% | 90.1% | 98.50 |
| 23 | Rabusertib | 9.9% | 90.1% | 98.74 |
| 24 | Ribociclib | 9.5% | 90.5% | 99.25 |
| 25 | Binimetinib | 8.7% | 91.3% | 100.00 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Ponatinib | 100.0% | 98.4% | +1.6% |
| Repotrectinib | 100.0% | 98.9% | +1.1% |
| Entrectinib | 97.1% | 99.0% | -2.0% |
| Darovasertib | 92.9% | — | — |
| Cabozantinib | 89.6% | 93.6% | -4.0% |
| Nintedanib | 63.2% | 93.8% | -30.6% |
| Pralsetinib | 56.7% | 98.7% | -42.0% |
| Defactinib | 47.3% | 80.3% | -33.1% |
| Ripretinib | 40.0% | 93.6% | -53.5% |
| Crizotinib | 37.0% | 95.8% | -58.8% |
| Sorafenib | 27.6% | — | — |
| Alpelisib | 26.8% | 97.5% | -70.7% |
| Tivozanib | 21.7% | 85.7% | -63.9% |
| Bosutinib | 21.3% | 67.0% | -45.7% |
| Fedratinib | 19.1% | 56.2% | -37.1% |
| Tenalisib | 14.1% | 59.0% | -44.9% |
| Regorafenib | 13.7% | — | — |
| Pacritinib | 13.7% | 89.4% | -75.7% |
| Ruxolitinib | 13.6% | — | — |
| Sunitinib | 12.9% | 82.8% | -69.9% |
| Duvelisib | 10.1% | — | — |
| Encorafenib | 9.9% | — | — |
| Rabusertib | 9.9% | — | — |
| Ribociclib | 9.5% | — | — |
| Binimetinib | 8.7% | — | — |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 12.9ms